Suppr超能文献

黑人与白人经药物洗脱支架治疗后的长期临床结局比较。

Comparison of Long-Term Clinical Outcomes After Drug-Eluting Stenting in Blacks-vs-Whites.

机构信息

Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.

Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.

出版信息

Am J Cardiol. 2019 Oct 15;124(8):1179-1185. doi: 10.1016/j.amjcard.2019.07.020. Epub 2019 Jul 25.

Abstract

Patients of different racial backgrounds may have socioeconomic, cultural, or genetic differences that impact outcomes after percutaneous coronary intervention (PCI). There are limited data beyond 2 to 3 years for Blacks to inform discussions and perhaps improve outcomes. We studied consecutive limus-stent treated patients, having their first PCI at our institution January 2003 to March 2010 in 2 cohorts; Cohort 1: standard 3-year follow-up (n = 3,782, 12.4% Blacks) and Cohort 2: from nearby zip codes with intended detailed follow-up through 8 to 13 years (n = 616, 31.8% Blacks). The primary outcomes of interest were mortality and death/MI/revascularization (DMIR) (Cohort 1) or major adverse cardiac events (cardiac DMIR) (Cohort 2). In all cohorts, Blacks had a higher prevalence of many risk factors. In Cohort 1, 3-year mortalities were 14.6% and 9.6% (p = 0.001) and DMIR were 32.1% and 25.0% (p = 0.001), for Blacks and Whites, respectively. In Cohort 2, over 9.5 ± 2.0 years, treatment intensity was as high or higher for Blacks, but they continued to have higher low-density lipoprotein-cholesterol and blood pressure values. Major adverse cardiac events and mortality at 10 years were higher for Blacks (59.0% vs 48.1%, p = 0.024 and 44.3% vs 23.0%, p < 0.001). Differences in outcomes, except 10 year mortality, were not significantly different after adjustment for baseline characteristics. Blacks have a higher risk profile at the time of PCI and worse long-term outcomes after drug-eluting stent, most of which is explained by baseline differences.

摘要

不同种族背景的患者可能存在社会经济、文化或遗传差异,这些差异会影响经皮冠状动脉介入治疗(PCI)后的结果。黑人患者的随访数据在 2 至 3 年以上的数据有限,这可能会影响讨论并改善结果。我们研究了连续接受雷帕霉素药物洗脱支架治疗的患者,他们在 2003 年 1 月至 2010 年 3 月期间在我们的机构进行了首次 PCI,分为两个队列;队列 1:标准 3 年随访(n=3782,黑人占 12.4%)和队列 2:附近邮编的患者,预期通过 8 至 13 年的详细随访(n=616,黑人占 31.8%)。主要观察终点为死亡率和死亡/心肌梗死/血运重建(DMIR)(队列 1)或主要不良心脏事件(心脏 DMIR)(队列 2)。在所有队列中,黑人患者都有更高的多种风险因素。在队列 1 中,黑人患者的 3 年死亡率分别为 14.6%和 9.6%(p=0.001),DMIR 分别为 32.1%和 25.0%(p=0.001)。在队列 2 中,经过 9.5±2.0 年的随访,黑人患者的治疗强度与白人患者一样高或更高,但他们的低密度脂蛋白胆固醇和血压值仍较高。黑人患者的主要不良心脏事件和 10 年死亡率更高(59.0%比 48.1%,p=0.024 和 44.3%比 23.0%,p<0.001)。在调整了基线特征后,除了 10 年死亡率,黑人患者的预后仍较差,但结果差异无统计学意义。黑人患者在接受 PCI 时的风险特征更高,在接受药物洗脱支架后长期预后更差,这在很大程度上可以用基线差异来解释。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验